Key result
Disease-modifying drugs for relapsing-remitting multiple sclerosis require a tailored decision-making approach for initiation timing based on unique disease and treatment characteristics.
Why the study?
When should disease-modifying drugs be initiated in adults with relapsing remitting multiple sclerosis?
When should disease-modifying drugs be initiated in adults with relapsing remitting multiple sclerosis?
This review provides a suggested approach for decision-making regarding the optimal timing to initiate disease-modifying therapies in adults with relapsing remitting multiple sclerosis.
For patients with Relapsing Remitting Multiple Scierosis Beta Interfaerons and Glatiramer Acetate were the first to be licensed for treatment. This review deals with one major question: when to initiate therapy? Through exploring the unique characteristics of the disease and treatement we suggest an approach that should be helpful in the process of decision-making.
No takes yet. Share an insight, caveat, or question.
Alkhawajah et al. (2011) studied this question. Disease-modifying drugs for relapsing-remitting multiple sclerosis require a tailored decision-making approach for initiation timing based on unique disease and treatment characteristics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: